13F Portfolios

Eagle Health Investments LP: TERNS PHARMACEUTICALS INC (TERN): Quarterly 13F Position History

As of Q1 2026, Eagle Health Investments LP reported 412,497 shares of TERNS PHARMACEUTICALS INC (TERN), worth $21.7M and representing 4.6% of its 13F equity book. Quarter-over-quarter share count change: + 137,407 (+49.9%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.

Recent initiation: Eagle Health Investments LP first reported TERN on the Q4 2025 filing — fewer than three quarters of history are available.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 412,497 +137,407 +49.9% $21.7M 4.6% $52.7
Q4 2025 275,090 $11.1M 2.4% $40.4

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Eagle Health Investments LP first disclose a TERN position in 13F-HR filings?

Eagle Health Investments LP first reported TERNS PHARMACEUTICALS INC (TERN) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.

What was Eagle Health Investments LP's most recent quarter-over-quarter share-count change in TERN?

Between Q4 2025 and Q1 2026, Eagle Health Investments LP added 137,407 shares of TERN (+49.9%), bringing the total reported position to 412,497 shares at a market value of $21.7M.

Does the implied price-per-share represent Eagle Health Investments LP's cost basis in TERN?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.